Close Menu

Government-performed comparative drug studies are bad because the results not only affect Medicare but the private market as well, writes American Enterprise Institute fellow Scott Gottlieb in an op-ed for the Wall Street Journal. A provision for a new federal center to study the economics of drug choices (part of the State Children's Health Insurance Program) will give misleading results and the data will not be transparent, argues Gottlieb, drawing on past studies such as

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.